Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

References

• ScullyMHuntBJBenjaminSBritish committee for standards in haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathiesBr J Haematol2012158332333510.1111/j.1365-2141.2012.09167.x22624596
   PubMed Web of Science ®Google Scholar
• RizzoCRizzoSScirèEThrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchangeBlood Transfus201210452153210.2450/2012.013S22790258
   PubMed Web of Science ®Google Scholar
• BellWRBraineHGNessPMKicklerTSImproved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patientsN Engl J Med1991325639840310.1056/NEJM1991080832506052062331
   PubMed Web of Science ®Google Scholar
• NguyenLLiXDuvallDTerrellDRVeselySKGeorgeJNTwice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006Transfusion200848234935710.1111/j.1537-2995.2007.01530.x18028271
   PubMed Web of Science ®Google Scholar
• BalduiniCLGugliottaLLuppiMItalian TTP study group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized studyAnn Hematol201089659159610.1007/s00277-009-0877-520033409
   PubMed Web of Science ®Google Scholar
• ÖngörenSSalihoğluAApaydınTVincristine as an adjunct to therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a single-institution experienceBalkan Med J201835641742110.4274/balkanmedj.2017.121529966997
   PubMed Web of Science ®Google Scholar
• ZimanAMitriMKlapperEPepkowitzSHGoldfingerDCombination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution’s experience and review of the literatureTransfusion2005451414910.1111/j.1537-2995.2005.03146.x15647017
   PubMed Web of Science ®Google Scholar
• BeloncleFBuffetMCoindreJ-PThrombotic microangiopathies reference center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experienceTransfusion201252112436244410.1111/j.1537-2995.2012.03578.x22404639
   PubMed Web of Science ®Google Scholar
• YilmazMEskazanAEUnsalACyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literatureTransfusion20135371586159310.1111/j.1537-2995.2012.03944.x23121663
   PubMed Web of Science ®Google Scholar
• CatalandSRJinMFerketichAKAn evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpuraBr J Haematol2007136114614910.1111/j.1365-2141.2006.06384.x17069579
   PubMed Web of Science ®Google Scholar
• Kappers-KlunneMCWijermansPFijnheerRSplenectomy for the treatment of thrombotic thrombocytopenic purpuraBr J Haematol2005130576877610.1111/j.1365-2141.2005.05681.x16115135
   PubMed Web of Science ®Google Scholar
• LimWVeselySKGeorgeJNThe role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraBlood2015125101526153110.1182/blood-2014-10-55921125573992
   PubMed Web of Science ®Google Scholar
• Vazquez-MelladoAPequeño-LuévanoMCantu-RodriguezOGMore about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpuraHematology201621531131610.1080/10245332.2015.113300826907228
   PubMed Web of Science ®Google Scholar
• ScullyMMcDonaldVCavenaghJA phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpuraBlood201111871746175310.1182/blood-2011-03-34113121636861
   PubMed Web of Science ®Google Scholar
• PageEEKremer HovingaJATerrellDRVeselySKGeorgeJNRituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpuraBlood2016127243092309410.1182/blood-2016-03-70382727060171
   PubMed Web of Science ®Google Scholar
• HieMGayJGalicierLFrench thrombotic microangiopathies reference centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpuraBlood2014124220421010.1182/blood-2014-01-55024424869941
   PubMed Web of Science ®Google Scholar
• RottenstreichAHochberg-KleinSRundDKalishYThe role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpuraJ Thromb Thrombol201641467868310.1007/s11239-015-1259-6
   PubMed Web of Science ®Google Scholar
• EskazanAEBortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpuraAnn Hematol201695111751175610.1007/s00277-016-2804-x27590601
   PubMed Web of Science ®Google Scholar
• MasiasCCatalandSRNovel therapies in thrombotic thrombocytopenic purpuraRes Pract Thromb Haemost201721192610.1002/rth2.1206630046703
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCablivi (caplacizumab): summary of product characteristics2018 Available from: http://www.ema.europa.euAccessed October 8, 2018
   Google Scholar
• UlrichtsHSilenceKSchoolmeesterAAntithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsBlood2011118375776510.1182/blood-2010-11-31785921576702
   PubMed Web of Science ®Google Scholar
• CallewaertFRoodtJUlrichtsHEvaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpuraBlood2012120173603361010.1182/blood-2012-04-42094322948047
   PubMed Web of Science ®Google Scholar
• DugganSCaplacizumab: first global approvalDrugs201878151639164210.1007/s40265-018-0989-030298461
   PubMed Web of Science ®Google Scholar
• PeyvandiFScullyMKremer HovingaJATITAN investigators. caplacizumab for acquired thrombotic thrombocytopenic purpuraN Engl J Med2016374651152210.1056/NEJMoa150553326863353
   PubMed Web of Science ®Google Scholar
• ScullyMCatalandSRPeyvandiFResults of the randomized, double-blind, placebo-controlled, phase 3 HERCULES study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura [abstract no. LBA-1 plus presentation]Blood2017130128684444
   PubMed Web of Science ®Google Scholar
• ScullyMCatalandSRPeyvandiFHERCULES investigators. caplacizumab treatment for acquired thrombotic thrombocyto-penic purpuraN Engl J Med2019380433534610.1056/NEJMoa180631130625070
   PubMed Web of Science ®Google Scholar
• WestwoodJPWebsterHMcGuckinSMcDonaldVMachinSJScullyMRituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapseJ Thromb Haemost201311348149010.1111/jth.1211423279219
   PubMed Web of Science ®Google Scholar
• PeyvandiFLavoretanoSPallaRADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remissionHaematologica200893223223910.3324/haematol.1173918223285
   PubMed Web of Science ®Google Scholar
• FerrariSScheiflingerFRiegerMFrench clinical and biological network on adult thrombotic microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activityBlood200710972815282210.1182/blood-2006-02-00606417164349
   PubMed Web of Science ®Google Scholar
• PeyvandiFScullyMKremer HovingaJACaplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpuraJ Thromb Haemost20171571448145210.1111/jth.1371628445600
   PubMed Web of Science ®Google Scholar
• PeyvandiFCatalandSRScullyMIntegrated efficacy results from the phase II and phase III studies with caplacizumab in patients with acquired thrombotic thrombocytopenic purpuraBlood2018132373 abstract
   Web of Science ®Google Scholar
• CatalandSRScullyMPeyvandiFRisk factors and manageability of the mainly mild mucocutaneous bleeding profile observed in aTTP patients treated with caplacizumab during the phase III hercules studyBlood20181321142 abstract
   Web of Science ®Google Scholar
• KnöblPScullyMCatalandSRIntegrated safety results from the phase II and phase III studies with caplacizumab in patients with acquired thrombotic thrombocytopenic purpuraBlood20181323739 abstract
   Web of Science ®Google Scholar
• Kremer HovingaJAScullyMCatalandSRSafety of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura – results normalized to time of exposure in a double-blind, placebo-controlled, phase 3 hercules studyBlood20181323744 abstract
   Web of Science ®Google Scholar